Trial Profile
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Aug 2019
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms PHOENIX-2
- Sponsors Centocor
- 09 Feb 2019 1-year safety data from 12 ustekinumab registrational trials published in the Drug Safety.
- 08 Mar 2016 Results of pooled analysis assessing the association between HLA-Cw6 status and efficacy of ustekinumab from Phoenix 1, Phoenix 2, and ACCEPT studies, presented at the 74th Annual Meeting of the American Academy of Dermatology.
- 28 Sep 2012 Safety data from a pooled analysis of this and the PHOENIX-1 and ACCEPT trials were presented at the 21st European Academy of Dermatology and Venereology (EADV) congress in late September 2012.